NL-OMON38440已完成2 期
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT) - A7281009 (9002/0123)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.;2. Subjects are willing and able to participate in the study, complete subject assessments, attend scheduled clinic visits, and comply with all protocol requirements as evidenced by written informed consent.;3. Male and/or female subjects between the ages of *18 and *65 years at the time of informed consent.;4. A diagnosis of UC for *3 months. A biopsy report must be available to confirm the histological diagnosis in the subject*s source documentation. In addition, a report documenting disease duration and extent of disease (e.g., proctosigmoiditis, left-sided colitis and pancolitis) based upon prior colonoscopy must also be available in source documentation. NOTE: A colonoscopy with biopsy will need to be performed, if this documentation is not available. ;5. Must have a flexible sigmoidoscopy (or colonoscopy, if preferred) indicative of active UC (Mayo endoscopic subscore of at least 2) during screening after all other inclusion criteria have been met. ;6. Must have active disease beyond the rectum (>15 cm of active disease at the Screening endoscopy).;7. Must have active UC with a Total Mayo Score of 6 to 12 points and moderate to severe disease on endoscopy (Mayo endoscopic subscore of at least 2).;8. Must have failed or been intolerant of at least one conventional therapy such as mesalamine, steroids and immunosuppressants (AZA, 6-MP or MTX) or anti-TNF. Subjects will be stratified based upon prior experience with anti-TNFs (naïve or experienced). Documentation of the current and prior UC treatment (ie, steroids and immunosuppressants) will be captured for additional analyses and must be provided in the source documentation.
排除标准
- •1. Subjects with a diagnosis of indeterminate colitis or Crohn*s disease. Subjects with clinical findings suggestive of Crohn*s disease, e.g., fistulae or granulomas on biopsy are also excluded.;2. Subjects with an imminent need for or planned surgery.;3. Subjects with colonic dysplasia or neoplasia.;4. Subjects with toxic megacolon.;5. Subjects with primary sclerosing cholangitis.;6. Subjects with known colonic stricture.;7. Subjects with a history of colonic or small bowel obstruction or resection.;8. Abnormal findings on the chest x-ray film performed routinely before initiating a new biologic therapy, such as presence of tuberculosis (TB), general infections, heart failure, or malignancy. (Chest x-ray examination may be performed up to 12 weeks prior to study entry (screening). Documentation of the official reading must be located and available in the source documentation).;9. Any history or current evidence of latent or active tuberculosis infection, evidence of prior or currently active tuberculosis by chest radiography, residing with or frequent close contact with individual(s) with active tuberculosis. Subjects who have a positive Mantoux (PPD) tuberculin skin test or a positive Interferon Gamma Release Assay (IGRA to be tested at the site*s local lab) during screening or within 12 weeks prior to randomization. The following are acceptable assays: QuantiFERON® - TB Gold test (QFT-G), QuantiFERON® - TB Gold In-Tube test (QFT-GIT) and T-SPOT®-TB test) during screening or within 12 weeks prior to screening.;10. Presence of active enteric infections (positive stool culture and sensitivity).
研究者
相似试验
进行中（未招募）
1 期
A study to assess the safety and efficacy of Lacosamide versus placebo (a pill without active medication) in patients with idiopathic generalised epilepsy who are already taking anti-epileptic medicationsEpilepsyEUCTR2011-003100-21-SKCB BIOSCIENCES, Inc.250
进行中（未招募）
1 期
Study to test whether PF-00547659 is safe and improves symptoms in patients with UClcerative Colitis (UC)MedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-002030-37-BGPfizer Inc, 235 East 42nd Street, New York, NY10017, United States300
进行中（未招募）
1 期
A study to assess the safety and efficacy of Lacosamide versus placebo (a pill without active medication) in patients with idiopathic generalised epilepsy who are already taking anti-epileptic medicationsMedDRA version: 20.0Level: LLTClassification code 10071096Term: Idiopathic generalized epilepsySystem Organ Class: 100000004852EpilepsyEUCTR2011-003100-21-Outside-EU/EEACB BIOSCIENCES, Inc.242
进行中（未招募）
不适用
Study to test whether PF-00547659 is safe and improves symptoms in patients with UCEUCTR2012-002030-37-SEPfizer Inc, 235 East 42nd Street, New York, NY10017, United States300
进行中（未招募）
1 期
A study to assess the safety and efficacy of Lacosamide versus placebo (a pill without active medication) in patients with idiopathic generalised epilepsy who are already taking anti-epileptic medicationsMedDRA version: 20.0 Level: LLT Classification code 10071096 Term: Idiopathic generalized epilepsy System Organ Class: 100000004852EpilepsyEUCTR2011-003100-21-BGCB BIOSCIENCES, Inc.200